Background Tumor necrosis factor (TNF) is a proinflammatory cytokine involved in the
pathogenesis of rheumatoid arthritis, and antagonism of TNF may reduce the activity of the disease…

Background: In a phase II study, etanercept (recombinant human tumor necrosis factor
receptor [p75]:Fc fusion protein) safely produced rapid, dose-dependent improvement in …

… Chon, Lin, and Baumgartner hold stock and/or stock options in Amgen. Dr. Giannini has
been awarded a research grant (to Children's Hospital Medical Center) from Amgen for clinical …

Objective This study was undertaken to evaluate the long‐term safety and effectiveness of
etanercept alone or in combination with methotrexate (MTX) in children with selected …

OBJECTIVE: Therapeutics used to treat inflammatory diseases, including psoriatic arthritis (PsA),
may potentially interfere with normal immune system function. Immune system function …

OBJECTIVE: Patients with rheumatoid arthritis (RA) treated with etanercept (Enbrel) in controlled
studies of 3 to 6 months' duration had rapid and sustained improvement of their disease…

… Baumgartner, Park, and Mancini own stock and/or hold stock options in Amgen. Dr. Genovese
has received consultant fees, speaking fees, and/or honoraria (less than $10,000 each) …

Objectives: To determine the long term safety profile of the tumour necrosis factor (TNF)
antagonist etanercept in subjects with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or …

Objective. To evaluate persistence with anti-tumor necrosis factor (TNF) therapy and predictors
of discontinuation in patients with rheumatoid arthritis (RA). Methods. This retrospective …

Objective To evaluate the effects of long‐term etanercept treatment, with or without
methotrexate, on growth in children with selected categories of juvenile idiopathic arthritis (JIA). …